Granin Aggregation Inhibition via Metal Ion Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating Alzheimer's disease have focused primarily on beta-amyloid, a minor component of senile plaques, leading to limited success, as the major and more toxic component, granins, have been overlooked, resulting in a lack of effective treatments despite significant global expenditure.
Innovation Solution
The development of compositions and methods to inhibit the aggregation of granins from a low molecular weight form to a high molecular weight form, using compounds such as anthoxanthins, flavonoids, and stilbenoids to modulate or suppress the interaction of granins with metal ions, thereby preventing their toxic aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If research and development efforts focus primarily on beta-amyloid as the target protein, then the understanding of senile plaque formation is improved, but effective treatments for Alzheimer's disease are not achieved due to beta-amyloid being only a minor component
Solution Approach 1:
The patent inverts the conventional research approach by shifting focus from beta-amyloid (minor component) to granins (major component). Instead of continuing to target the previously studied protein, the invention identifies and targets the previously overlooked granin proteins as the primary therapeutic target, thereby resolving the contradiction between understanding plaque formation and achieving effective treatment
Solution Approach 2:
The patent extracts granins from the conventional research framework that centered on beta-amyloid. By isolating and identifying granins as the major component of senile plaques, the invention separates the true pathogenic target from the previously mistaken focus, enabling development of effective treatments based on the correct target protein
2Duration of action of stationary object
If the focus remains on beta-amyloid despite it being a minor component, then research continuity is maintained, but granins which are much more abundant and toxic are overlooked
Solution Approach 1:
The patent changes the key parameter of research focus from beta-amyloid to granins based on compositional analysis. By altering which protein component is targeted, the invention resolves the contradiction between maintaining research continuity and recognizing the true major component, as the new focus on granins provides both continuity in studying senile plaques and correction of the component identification error
3Manufacturing precision
If therapeutic strategies target beta-amyloid aggregation, then the formation of senile plaques is studied, but the toxic aggregation of granins is not prevented
Solution Approach 1:
The patent introduces disaggregation compounds as intermediary agents that specifically target granin aggregation. These compounds act as mediators between the granin proteins and the desired therapeutic outcome, preventing toxic aggregation while maintaining the ability to study plaque formation. This resolves the contradiction by providing a specific mechanism to address granin toxicity without abandoning plaque formation research
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively reduce the pathogenesis of Alzheimer's disease by inhibiting granin aggregation, leading to potential partial cures and improved treatment options for the disease.
Implementation Method 1
compounds such as anthoxanthins, flavonoids, and stilbenoids to modulate or suppress the interaction of granins with metal ions, thereby preventing their toxic aggregation
Implementation Method 2
inhibit the aggregation of granins from a low molecular weight form to a high molecular weight form
Data Source
AI summary
Compositions for inhibiting the aggregation of a granin from a non-toxic low molecular weight form to a toxic high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form are provided. Such a composition typically includes one or more active compounds or agents, which may also be referred to herein as disaggregation compounds. Using the compounds and compositions described herein, methods of i) modulating, inhibiting or preventing the interaction of granins with metal ions, ii) modulating, inhibiting, preventing the aggregation of granins or dissociating aggregated granins, iii) reducing or inhibiting cell toxicity, iv) treating or preventing dementia or Alzheimer's disease, and v) preventing or treating Parkinson's and/or Huntington's diseases are also provided.